Here are the Form 4 insider transactions from Avalo Therapeutics, Inc. (AVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.
Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.
Avalo Therapeutics director Jonathan Goldman exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of Avalo Therapeutics common stock at an exercise price of $0.00 per share. This reflects a derivative exercise, not an open-market purchase or sale.
According to prior grant terms, Goldman received 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions. On March 16, 2026, she exercised options to acquire 19,500 shares of common stock at $12.65 per share and 5,992 shares at $8.04 per share.
The same day, she sold 25,492 shares of common stock in open-market transactions at an average price of about $16.1465 per share, in multiple trades between $16.00 and $16.34. Following these transactions, she directly holds 3,622 common shares.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki received a grant of stock options covering 80,000 shares on February 26, 2026. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the vesting terms, 25% of the option grant will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting is conditioned on Varki's continued service with the company on each applicable vesting date.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.
Boyd Taylor reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that its Chief Business Officer, Boyd Taylor, received a grant of stock options covering 95,000 shares. The options were awarded as a derivative security and are held directly.
The award vests 25% on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Boyd Taylor’s continued service on each vesting date.
Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.
The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.
NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.
Avalo Therapeutics, Inc. reported an insider Form 4 transaction by its Chief Medical Officer. On December 10, 2025, the officer disposed of 1,013 shares of Avalo Therapeutics common stock at $4.1 per share. After this transaction, the officer beneficially owns 3,622 shares, which include shares acquired pursuant to Avalo Therapeutics' Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics’ chief strategy officer reported a small change in personal share holdings. On 12/10/2025, the officer disposed of 637 shares of Avalo Therapeutics common stock at a price of $4.1 per share, according to an SEC insider ownership report.
After this transaction, the officer directly beneficially owns 2,655 shares of Avalo Therapeutics. These 2,655 shares are described as having been acquired under the company’s Employee Stock Purchase Plan as part of the reported activity, indicating ongoing participation in the company’s equity programs.
Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.
Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.
The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).
Avalo Therapeutics, Inc. (AVTX) reported insider activity by one of its directors involving common stock and stock options on November 14, 2025. The director exercised a stock option to acquire 8,200 shares of common stock at an exercise price of $9.88 per share and then sold those 8,200 shares at a weighted average price of $14.3474 per share. On the same date, the director also sold an additional 3,167 shares of common stock at $14.30 per share, for total reported sales of 11,367 shares. Following these transactions, the director reported owning 0 shares of common stock directly and 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034, which vest in three equal annual installments on March 28, 2025, 2026 and 2027.
Avalo Therapeutics insider stock option grant to Chief Business Officer — Boyd Taylor received a stock option on 10/01/2025
The option covers 275,000 shares of common stock with an exercise price of $12.96 and an expiration date of 10/01/2035. The award vests over four years: 25% vests on the first anniversary of the grant and the remainder vests in equal monthly installments over the next three years, subject to continued employment. Following the grant the reporting person beneficially owns 275,000 shares directly.
Avalo Therapeutics director Kevin Robert Lind was granted a stock option on 10/01/2025 to buy 40,200 shares of common stock at an exercise price of $12.96. The option becomes exercisable in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the director's continued service. The option expires on 10/01/2035 and the reporting Form 4 was filed on 10/02/2025 by power of attorney. The grant is reported as a direct holding and shows 40,200 shares underlying the derivative security following the transaction.
Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.
Form 4 overview: Avalo Therapeutics, Inc. (AVTX) filed a Form 4 disclosing an equity-based compensation grant to board member Samantha Truex on 06/17/2025. The filing reports no sales or disposals of common stock; it solely records the award of new derivative securities.
Key terms of the option grant
- Security: Stock Option (Right to Buy) on AVTX common shares
- Underlying shares: 20,100
- Exercise price: $4.47 per share
- Vesting schedule: 100 % cliff vest on the first anniversary of the grant date, conditional on Ms. Truex’s continued board service
- Expiration: 06/17/2035 (10-year term)
- Ownership form after transaction: Direct
The transaction increases Ms. Truex’s derivative beneficial ownership to 20,100 options. No non-derivative (common stock) positions are listed in this filing, and there is no indication of Rule 10b5-1 trading plan use.
Investor takeaway: The filing reflects routine board compensation rather than market activity. While the additional options further align the director’s incentives with shareholders, the relatively small size (≈20 k shares) suggests limited immediate impact on AVTX’s share float or insider-sentiment signals.
Form 4 filing overview: On 18 June 2025, Avalo Therapeutics, Inc. (AVTX) reported that director Mitchell Chan received a new equity award on 17 June 2025. The grant consists of 20,100 non-qualified stock options with an exercise price of $4.47 per share, expiring 17 June 2035. The option vests 100 % on the first anniversary of the grant date, provided the director remains in service at that time.
Post-transaction holdings: Following the grant, Chan directly beneficially owns 20,100 derivative securities (options). No acquisitions or dispositions of common shares were reported in Table I, so the filing only affects derivative ownership.
Implications for investors: The award is a routine component of board compensation that aligns the director’s incentives with shareholder interests by linking future gains to share price appreciation above $4.47. Although the 20,100-share underlying amount represents minimal potential dilution relative to Avalo’s outstanding share count, it does marginally increase fully-diluted share capital. No cash outflow or immediate EPS impact occurs because the options are non-cash grants and forfeiture is possible if service ceases before vesting.
Materiality assessment: The transaction is not a signal of insider buying or selling; rather, it is a standard equity grant with no direct indication of management’s near-term outlook. Consequently, its market impact should be limited, but it demonstrates continued board engagement and retention efforts.
Avalo Therapeutics director Jonathan Goldman received a new stock option grant on June 17, 2025. The derivative security details include:
- Granted 20,100 stock options to purchase common stock
- Exercise price set at $4.47 per share
- Options will vest 100% on June 17, 2026 (first anniversary of grant date)
- Expiration date is June 17, 2035
- Vesting is contingent on continued service as director
The Form 4 filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity ownership potential.
Insider Trading Alert: Avalo Therapeutics (AVTX) director Gilla Kaplan received a stock option grant on June 17, 2025. The derivative securities transaction involved 20,100 stock options with the following key terms:
- Exercise price set at $4.47 per share
- Options expire on June 17, 2035
- 100% vesting occurs on the first anniversary of grant date
- Vesting conditional on continued service as director
This Form 4 filing discloses a standard director compensation stock option grant, suggesting continued alignment of director interests with shareholders through equity-based compensation. The filing was signed by Donald R. Reynolds via Power of Attorney on June 18, 2025.
Avalo Therapeutics director Aaron Kantoff received a new stock option grant on June 17, 2025. The derivative security details include:
- Granted 20,100 stock options to purchase common stock
- Exercise price set at $4.47 per share
- Options will vest 100% on June 17, 2026 (first anniversary of grant date)
- Expiration date is June 17, 2035
- Vesting is contingent on continued service as director
This Form 4 filing was submitted by Donald R. Reynolds via power of attorney on June 18, 2025. The grant appears to be part of the company's director compensation program. The options represent a direct ownership interest and will become exercisable upon vesting.
Insider Trading Alert: Michael Thomas Heffernan, Director of Avalo Therapeutics (AVTX), was granted stock options on June 17, 2025. The transaction details include:
- Received 29,500 stock options to purchase common stock
- Exercise price set at $4.47 per share
- Options will vest 100% on June 17, 2026 (first anniversary of grant date)
- Options expire on June 17, 2035
- Vesting is contingent on continued service as Director
This Form 4 filing represents a standard director compensation grant and was reported within the required two-business-day filing window. The transaction was executed directly (not through indirect ownership) and was documented via power of attorney by Donald R. Reynolds.
Director Rita Jain of Avalo Therapeutics (AVTX) received a stock option grant on June 17, 2025, according to a Form 4 filing. The key details include:
- Granted 40,200 stock options to purchase common stock at an exercise price of $4.47 per share
- Options will vest in three equal installments on the first, second, and third anniversary of the grant date
- Options expire on June 17, 2035
- Vesting is contingent on continued service as director
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This transaction represents a new position for the director, as no prior holdings were reported.